Dasher Neuroscience completa el reclutamiento de pacientes en el ensayo clínico global de fase 2

Phase 2YA-101Positive

AI Analysis

Summary

Dasher Neuroscience completed patient recruitment for a global Phase 2 clinical trial of YA-101, an AI-based drug candidate for multiple system atrophy. The milestone represents progress toward advancing the treatment through clinical development.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Patient recruitment completed in global Phase 2 clinical trial

Importance:6/10

Sentiment:

0.60

Phase 2clinical trialpatient recruitmentAI-based drugneurological diseasemultiple system atrophy

Related Companies

$GBCYD

Read the original article

Published by PR Newswire Biotech on July 29, 2026 9:30 AM

Read Original